Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Platinum-Refractory Fallopian Tube Carcinoma × ASTX-660 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Platinum-Refractory Fallopian Tube Carcinoma 1 Lymphoma 1

Interventions

Taxes 1 Specimen Handling 1 Paclitaxel 1 Magnetic Resonance Spectroscopy 1 Immunoglobulin G 1 Disulfides 1 Bevacizumab 1 ASTX-660 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡